+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pseudomonas aeruginosa Pneumonia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 34 Pages
  • May 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5602709
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest disease pipeline guide Pseudomonas aeruginosa Pneumonia - Drugs In Development, 2022, provides an overview of the Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline landscape.

Pseudomonas aeruginosa has become an important cause of pneumonia. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system. Treatment includes antibiotics.

Report Highlights


The publisher's latest pipeline guide Pseudomonas aeruginosa Pneumonia - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Pneumonia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pseudomonas aeruginosa Pneumonia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Pneumonia (Infectious Disease)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Pneumonia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Pneumonia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of TablesList of FiguresIntroduction
Report Coverage
Pseudomonas aeruginosa Pneumonia - Overview
Pseudomonas aeruginosa Pneumonia - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Pseudomonas aeruginosa Pneumonia - Therapeutics Assessment
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pseudomonas aeruginosa Pneumonia - Companies Involved in Therapeutics Development
Aridis Pharmaceuticals Inc
Armata Pharmaceuticals Inc
AstraZeneca Plc
Ayuvis Research Inc
Pedanius Therapeutics Ltd
Pseudomonas aeruginosa Pneumonia - Drug Profiles
APPA-03 - Drug Profile
Product Description
Mechanism Of Action
AVR-86 - Drug Profile
Product Description
Mechanism Of Action
Gene Therapy for Pseudomonas aeruginosa Pneumonia - Drug Profile
Product Description
Mechanism Of Action
History of Events
panobacumab - Drug Profile
Product Description
Mechanism Of Action
History of Events
PED-014 - Drug Profile
Product Description
Mechanism Of Action
PED-015 - Drug Profile
Product Description
Mechanism Of Action
PED-019 - Drug Profile
Product Description
Mechanism Of Action
Recombinant Enzyme for Pseudomonas Aeruginosa Pneumonia - Drug Profile
Product Description
Mechanism Of Action
Pseudomonas aeruginosa Pneumonia - Dormant Projects
Pseudomonas aeruginosa Pneumonia - Discontinued Products
Pseudomonas aeruginosa Pneumonia - Product Development Milestones
Featured News
Sep 26, 2017: Study Investigates Novel Immunotherapeutic Delivery Strategy for Preventing Infection with Antibiotic Resistant Bacteria
AppendixMethodologyCoverageSecondary ResearchPrimary ResearchExpert Panel ValidationContact UsDisclaimer
List of Tables
  • Number of - Products under Development for Pseudomonas aeruginosa Pneumonia, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of - Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
Pseudomonas aeruginosa Pneumonia - Pipeline by Aridis Pharmaceuticals Inc, 2022
Pseudomonas aeruginosa Pneumonia - Pipeline by Armata Pharmaceuticals Inc, 2022
Pseudomonas aeruginosa Pneumonia - Pipeline by AstraZeneca Plc, 2022
Pseudomonas aeruginosa Pneumonia - Pipeline by Ayuvis Research Inc, 2022
Pseudomonas aeruginosa Pneumonia - Pipeline by Pedanius Therapeutics Ltd, 2022
Pseudomonas aeruginosa Pneumonia - Dormant Projects, 2022
Pseudomonas aeruginosa Pneumonia - Discontinued Products, 2022
List of Figures
  • Number of - Products under Development for Pseudomonas aeruginosa Pneumonia, 2022
  • Number of - Products under Development by Companies, 2022
  • Number of Products by Targets, 2022
  • Number of Products by Stage and Targets, 2022
  • Number of Products by Mechanism of Actions, 2022
  • Number of Products by Stage and Mechanism of Actions, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Molecule Types, 2022
  • Number of Products by Stage and Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Aridis Pharmaceuticals Inc
  • Armata Pharmaceuticals Inc
  • AstraZeneca Plc
  • Ayuvis Research Inc
  • Pedanius Therapeutics Ltd